NASDAQ:VSTM - Verastem Stock Price, Price Target & More

$4.15 +0.01 (+0.24 %)
(As of 04/20/2018 02:31 AM ET)
Previous Close$4.15
Today's Range$4.10 - $4.22
52-Week Range$1.71 - $5.71
Volume608,156 shs
Average Volume808,975 shs
Market Capitalization$212.54 million
P/E Ratio-2.36
Dividend YieldN/A
Beta2.23

About Verastem (NASDAQ:VSTM)

Verastem logoVerastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. Its defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. The company also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with hematologic cancers through the dual inhibition of PI3K delta and gamma. Its duvelisib is in Phase 3 randomized and late-and mid-stage clinical trials for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with double-refractory indolent non-Hodgkin lymphoma. The company has license agreements with Infinity Pharmaceuticals, Inc.; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Debt-to-Equity Ratio0.26%
Current Ratio5.13%
Quick Ratio5.13%

Price-To-Earnings

Trailing P/E Ratio-2.36
Forward P/E Ratio-2.86
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.19 per share
Price / Book3.49

Profitability

EPS (Most Recent Fiscal Year)($1.76)
Net Income$-67,800,000.00
Net MarginsN/A
Return on Equity-130.79%
Return on Assets-93.20%

Miscellaneous

Employees69
Outstanding Shares50,970,000

How to Become a New Pot Stock Millionaire

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem (NASDAQ:VSTM) released its quarterly earnings data on Tuesday, March, 13th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.01. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

8 brokerages have issued twelve-month price targets for Verastem's shares. Their forecasts range from $1.50 to $17.00. On average, they expect Verastem's stock price to reach $11.6429 in the next twelve months. View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:
  • 1. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (3/20/2018)
  • 2. Cantor Fitzgerald analysts commented, "Working off Overhangs. We think VSTM shares are undervalued relative to the duvelisib opportunity, and this is partly a function, in our view, of overhangs, particularly cash. VSTM had just under $87 mln in cash, which is sufficient to fund the company into 2H18, but will need additional capital to see duvelisib through commercialization. VSTM has an additional $35 mln available under a debt facility, and the company could add additional cash through a partner deal. It has been our anticipation that VSTM will need to address the capital markets in some way in 2018." (3/13/2018)
  • 3. Cann analysts commented, "Verastem announced today that a poster highlighting the synergistic effects of Duvelisib in combination with immune checkpoint or co-stimulatory antibodies in preclinical models of B cell lymphoma was presented at ASCO-SITC Clinical Immuno- Oncology Symposium. The purpose of this study was to evaluate whether Duvelisib therapy could augment the efficacy of immune checkpoint inhibitors or co-stimulatory agents in the A20 mouse model of B cell lymphoma. Verastem reported that as a result of beneficial changes within the tumor microenvironment, it observed enhancement by Duvelisib of the anti-tumor efficacy of immune checkpoint or co-stimulatory antibodies in this preclinical B cell lymphoma model." (1/26/2018)

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Chief Exec. Officer, Pres and Director (Age 54)
  • Ms. Julie B. Feder, Chief Financial Officer
  • Dr. NgocDiep T Le M.D., Ph.D., Chief Medical Officer
  • Mr. Richard H. Aldrich, Founder and Consultant (Age 64)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board

Has Verastem been receiving favorable news coverage?

News articles about VSTM stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Verastem earned a media sentiment score of 0.09 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $4.15.

How big of a company is Verastem?

Verastem has a market capitalization of $212.54 million. The biopharmaceutical company earns $-67,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Verastem employs 69 workers across the globe.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]


MarketBeat Community Rating for Verastem (VSTM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  445
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Verastem (NASDAQ:VSTM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Verastem in the last 12 months. Their average twelve-month price target is $11.6429, suggesting that the stock has a possible upside of 180.55%. The high price target for VSTM is $17.00 and the low price target for VSTM is $1.50. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.892.882.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.6429$10.9375$10.6429$7.75
Price Target Upside: 180.55% upside223.59% upside248.95% upside83.80% upside

Verastem (NASDAQ:VSTM) Consensus Price Target History

Price Target History for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2018Cantor FitzgeraldSet Price TargetBuy$17.00HighView Rating Details
3/23/2018B. RileySet Price TargetBuy$15.00LowView Rating Details
3/15/2018HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
1/26/2018CannReiterated RatingBuy$13.00LowView Rating Details
12/21/2017OppenheimerSet Price TargetBuy$13.00MediumView Rating Details
12/11/2017Raymond JamesReiterated RatingBuyHighView Rating Details
12/1/2017Roth CapitalInitiated CoverageBuy$12.00HighView Rating Details
6/28/2017Jefferies GroupReiterated RatingHold$1.50HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> Outperform$6.00HighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Verastem (NASDAQ:VSTM) Earnings History and Estimates Chart

Earnings by Quarter for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) Earnings Estimates

2018 EPS Consensus Estimate: ($1.56)
2019 EPS Consensus Estimate: ($1.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.47)($0.37)($0.42)
Q2 20182($0.38)($0.37)($0.38)
Q3 20182($0.39)($0.38)($0.39)
Q4 20182($0.41)($0.34)($0.38)
Q1 20191($0.64)($0.64)($0.64)
Q2 20191($0.21)($0.21)($0.21)
Q3 20191($0.18)($0.18)($0.18)
Q4 20191($0.11)($0.11)($0.11)

Verastem (NASDAQ VSTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.38)N/AView Earnings Details
3/13/2018Q4 2017($0.4210)($0.4330)ViewN/AView Earnings Details
11/7/2017Q3 2017($0.32)($0.61)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.36)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.3520)($0.35)ViewN/AView Earnings Details
3/23/2017Q4 2016($0.27)($0.32)ViewN/AView Earnings Details
11/7/2016Q3($0.24)($0.21)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
11/9/2015Q3 2015($0.43)($0.42)ViewN/AView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.52)($0.51)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.4420)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
3/27/2013Q4 2012($0.40)($0.39)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.36)($0.51)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.34)($0.34)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.28)($0.47)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Verastem (NASDAQ:VSTM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Verastem (NASDAQ VSTM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 31.65%
Insider Trading History for Verastem (NASDAQ:VSTM)
Insider Trading History for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ VSTM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2017Timothy J BarberichDirectorBuy60,538$3.95$239,125.10130,000View SEC Filing  
5/15/2017Timothy J BarberichDirectorBuy30,000$2.45$73,500.0069,462View SEC Filing  
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00408,142View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.0058,143View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00700,264View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00239,320View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00696,872View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00407,142View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00407,142View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00407,142View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00407,142View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00407,142View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00407,142View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00407,142View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00407,142View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00407,142View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00407,142View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00407,142View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Verastem (NASDAQ VSTM) News Headlines

Source:
DateHeadline
Cann Reaffirms Buy Rating for Verastem (VSTM)Cann Reaffirms Buy Rating for Verastem (VSTM)
www.americanbankingnews.com - April 16 at 1:54 PM
Verastem (VSTM) in Focus: Stock Moves 8% HigherVerastem (VSTM) in Focus: Stock Moves 8% Higher
finance.yahoo.com - April 13 at 5:31 PM
Are Things Finally Looking Up For Verastem?Are Things Finally Looking Up For Verastem?
seekingalpha.com - April 13 at 8:20 AM
2 Attractive Biotech Stocks Under $102 Attractive Biotech Stocks Under $10
seekingalpha.com - April 12 at 5:38 PM
Verastem: A Solid Player On A Crowded FieldVerastem: A Solid Player On A Crowded Field
seekingalpha.com - April 12 at 5:38 PM
Verastem Forecasted to Post FY2021 Earnings of $2.09 Per Share (VSTM)Verastem Forecasted to Post FY2021 Earnings of $2.09 Per Share (VSTM)
www.americanbankingnews.com - April 11 at 9:19 AM
3 Things In Biotech, April 10: Major Wins For Merck, AbbVie, And Verastem3 Things In Biotech, April 10: Major Wins For Merck, AbbVie, And Verastem
seekingalpha.com - April 11 at 8:32 AM
HC Wainwright Analysts Give Verastem (VSTM) a $7.00 Price TargetHC Wainwright Analysts Give Verastem (VSTM) a $7.00 Price Target
www.americanbankingnews.com - April 10 at 11:38 PM
Verastem (VSTM) Reports Acceptance of NDA for Duvelisib and Grants Priority ReviewVerastem (VSTM) Reports Acceptance of NDA for Duvelisib and Grants Priority Review
www.streetinsider.com - April 9 at 5:20 PM
Cantor Fitzgerald Analysts Give Verastem (VSTM) a $17.00 Price TargetCantor Fitzgerald Analysts Give Verastem (VSTM) a $17.00 Price Target
www.americanbankingnews.com - April 9 at 9:23 AM
Verastem (VSTM) PT Set at $17.00 by Cantor FitzgeraldVerastem (VSTM) PT Set at $17.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 6 at 9:50 PM
-$0.41 Earnings Per Share Expected for Verastem (VSTM) This Quarter-$0.41 Earnings Per Share Expected for Verastem (VSTM) This Quarter
www.americanbankingnews.com - April 3 at 11:33 PM
Verastem (VSTM) Given Average Rating of "Buy" by AnalystsVerastem (VSTM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 1 at 5:34 AM
Verastem to Present at the HC Wainwright Global Life Sciences ConferenceVerastem to Present at the HC Wainwright Global Life Sciences Conference
www.businesswire.com - March 29 at 8:29 AM
Verastem Inc (VSTM) Expected to Earn Q1 2019 Earnings of ($0.64) Per ShareVerastem Inc (VSTM) Expected to Earn Q1 2019 Earnings of ($0.64) Per Share
www.americanbankingnews.com - March 26 at 1:39 AM
Verastem (VSTM) Given a $15.00 Price Target by B. Riley AnalystsVerastem (VSTM) Given a $15.00 Price Target by B. Riley Analysts
www.americanbankingnews.com - March 23 at 1:30 PM
FY2021 EPS Estimates for Verastem Inc Boosted by Analyst (VSTM)FY2021 EPS Estimates for Verastem Inc Boosted by Analyst (VSTM)
www.americanbankingnews.com - March 22 at 5:52 PM
Verastem (VSTM) Rating Lowered to Hold at Zacks Investment ResearchVerastem (VSTM) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 20 at 1:50 PM
Verastem In CLL: Opportunity And Caution - Seeking AlphaVerastem In CLL: Opportunity And Caution - Seeking Alpha
seekingalpha.com - March 20 at 8:29 AM
Verastem (VSTM) Rating Increased to Buy at Zacks Investment ResearchVerastem (VSTM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 17 at 10:30 AM
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
www.zacks.com - March 16 at 6:28 PM
Verastem Inc Forecasted to Post Q2 2018 Earnings of ($0.38) Per Share (VSTM)Verastem Inc Forecasted to Post Q2 2018 Earnings of ($0.38) Per Share (VSTM)
www.americanbankingnews.com - March 16 at 8:52 AM
Verastem (VSTM) Given a $10.00 Price Target at HC WainwrightVerastem (VSTM) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 15 at 10:30 PM
FY2021 EPS Estimates for Verastem Inc Reduced by Oppenheimer (VSTM)FY2021 EPS Estimates for Verastem Inc Reduced by Oppenheimer (VSTM)
www.americanbankingnews.com - March 15 at 2:52 PM
Verastem Updates Presentation Time for Oppenheimer & Co. Healthcare ConferenceVerastem Updates Presentation Time for Oppenheimer & Co. Healthcare Conference
finance.yahoo.com - March 14 at 7:06 PM
Verastem (VSTM) Announces Quarterly  Earnings Results, Misses Estimates By $0.01 EPSVerastem (VSTM) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - March 14 at 12:20 PM
Verastem to Present at Upcoming Conferences - Business Wire (press release)Verastem to Present at Upcoming Conferences - Business Wire (press release)
www.businesswire.com - March 14 at 8:34 AM
Verastem to Present at Upcoming ConferencesVerastem to Present at Upcoming Conferences
finance.yahoo.com - March 14 at 8:34 AM
Verastem (VSTM) Earns "Buy" Rating from Cantor FitzgeraldVerastem (VSTM) Earns "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - March 13 at 6:22 PM
Verastem Reports Year-End 2017 Financial Results - Business Wire (press release)Verastem Reports Year-End 2017 Financial Results - Business Wire (press release)
www.businesswire.com - March 13 at 8:27 AM
Verastem Reports Year-End 2017 Financial ResultsVerastem Reports Year-End 2017 Financial Results
finance.yahoo.com - March 13 at 8:27 AM
Verastem Inc (VSTM) Forecasted to Earn FY2017 Earnings of ($1.72) Per ShareVerastem Inc (VSTM) Forecasted to Earn FY2017 Earnings of ($1.72) Per Share
www.americanbankingnews.com - March 12 at 1:16 AM
B. Riley Initiates Coverage on Verastem (VSTM)B. Riley Initiates Coverage on Verastem (VSTM)
www.americanbankingnews.com - March 10 at 8:48 PM
Verastem Inc (VSTM) Receives Average Rating of "Buy" from BrokeragesVerastem Inc (VSTM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 7 at 5:48 AM
Head to Head Contrast: Verastem (VSTM) & Obseva (OBSV)Head to Head Contrast: Verastem (VSTM) & Obseva (OBSV)
www.americanbankingnews.com - March 3 at 5:30 PM
Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 2 at 6:09 PM
Verastem Inc (VSTM) Expected to Announce Earnings of -$0.43 Per ShareVerastem Inc (VSTM) Expected to Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - February 28 at 7:08 PM
Verastem (VSTM) Upgraded to "Hold" at Zacks Investment ResearchVerastem (VSTM) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 28 at 1:06 PM
Verastem to Present at the 30 - Business Wire (press release)Verastem to Present at the 30 - Business Wire (press release)
www.businesswire.com - February 26 at 8:18 AM
Verastem to Present at the 30th Annual ROTH ConferenceVerastem to Present at the 30th Annual ROTH Conference
finance.yahoo.com - February 26 at 8:18 AM
Verastem (VSTM) Downgraded by Zacks Investment Research to SellVerastem (VSTM) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - February 21 at 12:02 PM
FY2020 EPS Estimates for Verastem Inc (VSTM) Raised by OppenheimerFY2020 EPS Estimates for Verastem Inc (VSTM) Raised by Oppenheimer
www.americanbankingnews.com - February 12 at 9:20 AM
Verastem Inc (VSTM) Receives Average Recommendation of "Buy" from AnalystsVerastem Inc (VSTM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 10 at 5:38 AM
Verastem (VSTM) Receives "Buy" Rating from Cantor FitzgeraldVerastem (VSTM) Receives "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - February 7 at 11:30 AM
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - February 7 at 9:41 AM
Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular LymphomaVerastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
finance.yahoo.com - February 7 at 9:41 AM
Verastem submits U.S. marketing application for lead candidate duvelisib; shares ahead 7% premarketVerastem submits U.S. marketing application for lead candidate duvelisib; shares ahead 7% premarket
seekingalpha.com - February 7 at 8:17 AM
Verastem Inc (VSTM) Short Interest UpdateVerastem Inc (VSTM) Short Interest Update
www.americanbankingnews.com - January 28 at 1:06 AM
Verastem (VSTM) Stock Rating Reaffirmed by CannVerastem (VSTM) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - January 26 at 8:08 PM
Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma ModelVerastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model
finance.yahoo.com - January 26 at 3:44 PM

SEC Filings

Verastem (NASDAQ:VSTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Verastem (NASDAQ:VSTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Verastem (NASDAQ VSTM) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.